» Articles » PMID: 17110500

Kinins Promote B2 Receptor Endocytosis and Delay Constitutive B1 Receptor Endocytosis

Overview
Journal Mol Pharmacol
Date 2006 Nov 18
PMID 17110500
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Upon sustained insult, kinins are released and many kinin responses, such as inflammatory pain, adapt from a B2 receptor (B2R) type in the acute phase to a B1 receptor (B1R) type in the chronic phase. In this study, we show that kinins modulate receptor endocytosis to rapidly decrease B2R and increase B1R on the cell surface. B2Rs, which require agonist for activity, are stable plasma membrane components without agonist but recruit beta-arrestin 2, internalize in a clathrin-dependent manner, and recycle rapidly upon agonist treatment. In contrast, B1Rs, which are inducible and constitutively active, constitutively internalize without agonist via a clathrin-dependent pathway, do not recruit beta-arrestin 2, bind G protein-coupled receptor sorting protein, and target lysosomes for degradation. Agonist delays B1R endocytosis, thus transiently stabilizing the receptor. Most of the receptor trafficking phenotypes are transplantable from one receptor to the other through exchange of the C-terminal receptor tails, indicating that the tails contain epitopes that are important for the binding of protein partners that participate in the endocytic and postendocytic receptor choices. It is noteworthy that the agonist delay of B1R endocytosis is not transplanted to the B2R via the B1R tail, suggesting that this property of the B1R requires another domain. These events provide a rapid kinin-dependent mechanism for 1) regulating the constitutive B1R activity and 2) shifting the balance of accessible receptors in favor of B1R.

Citing Articles

Novel Pharmacology Following Heteromerization of the Angiotensin II Type 2 Receptor and the Bradykinin Type 2 Receptor.

Johnstone E, Ayoub M, Hertzman R, See H, Abhayawardana R, Seeber R Front Endocrinol (Lausanne). 2022; 13:848816.

PMID: 35721749 PMC: 9204302. DOI: 10.3389/fendo.2022.848816.


A comprehensive review on current understanding of bradykinin in COVID-19 and inflammatory diseases.

Rex D, Vaid N, Deepak K, Dagamajalu S, Keshava Prasad T Mol Biol Rep. 2022; 49(10):9915-9927.

PMID: 35596055 PMC: 9122735. DOI: 10.1007/s11033-022-07539-2.


Binding Mode Exploration of B1 Receptor Antagonists' by the Use of Molecular Dynamics and Docking Simulation-How Different Target Engagement Can Determine Different Biological Effects.

Gemei M, Talarico C, Brandolini L, Manelfi C, Za L, Bovolenta S Int J Mol Sci. 2020; 21(20).

PMID: 33081372 PMC: 7590058. DOI: 10.3390/ijms21207677.


Pharmacological Profile of a New Small Molecule Bradykinin B Receptor Antagonist.

Lesage A, Gibson C, Marceau F, Ambrosi H, Saupe J, Katzer W Front Pharmacol. 2020; 11:916.

PMID: 32636746 PMC: 7316994. DOI: 10.3389/fphar.2020.00916.


GPRASP proteins are critical negative regulators of hematopoietic stem cell transplantation.

Morales-Hernandez A, Benaksas C, Chabot A, Caprio C, Ferdous M, Zhao X Blood. 2020; 135(14):1111-1123.

PMID: 32027737 PMC: 7118811. DOI: 10.1182/blood.2019003435.